Clinical Utility of Electrical Impedance Spectroscopy

Inclusion Criteria:

* The lesion(s) meet criteria for Nevisense evaluation.
* Lesions that present with unclear clinical presentation to allow for clinical diagnosis of benign or minimally dysplastic nevus (nevi) -Thus, necessitating a biopsy.
* Lesions within Nevisense indication for use: Nevisense is indicated for use on cutaneous lesions with one or more clinical or historical characteristics of melanoma, when a dermatologist chooses to obtain additional information when considering biopsy. Nevisense should not be used on clinically obvious melanoma. The Nevisense result is one element of the overall clinical assessment. The output of Nevisense should be used in combination with clinical and historical signs of melanoma to obtain additional information prior to a decision to biopsy. Nevisense is indicated only for use on:

  * primary skin lesions with a diameter between 2 mm and 20 mm;
  * lesions that are accessible by the Nevisense probe;
  * lesions where the skin is intact (i.e. non-ulcerated or non-bleeding lesions);
  * lesions that do not contain a scar or fibrosis consistent with previous trauma;
  * lesions not located in areas of psoriasis, eczema, acute sunburn or similar skin conditions;
  * lesions not in hair-covered areas;
  * lesions which do not contain foreign matter;
  * lesions not on special anatomic sites (i.e. not for use on acral skin, genitalia, eyes, mucosal areas).

Exclusion Criteria:

* Subjects who fail to provide informed consent
* Study subjects with underlying medical disease which may alter ability to diagnose clinically or inhibit Nevisense from collecting data